CCS1477, a new selective inhibitor of the p300/CBP bromodomain, blocks AR and AR-Vs signaling in the cell line, patient-derive xenografts [95], and in serial tumor biopsies from an ongoing phase I clinical trial [96]. This evidence concerns the gene EP300 and neoplasm.